
Beta Bionics Faces Class Action Over Alleged Concealment of FDA Warnings
A 72% collapse in Beta Bionics shares has triggered a securities class action lawsuit, with investors alleging the company hid a June 2025 FDA Form 483 and over 18,000 customer complaints regarding its iLet Bionic Pancreas, causing hundreds of millions in market capitalization to evaporate between July 2025 and February 2026.
























